acute heart failure

systematic review meta-analysis network meta-analysis

Select diureticsultrafiltrationpositive inotropic agent atrial natriuretic peptide calcium sensitiserendothelin receptor antagonist new drug under developmentrelaxinvasodilators therapyvasopressin antagonist All type of patient       beta-blockersendothelin receptor antagonisthuman B-type natriuretic peptidelevosimendanoral vasopressin antagonistrelaxineselective adenosine-1 receptor antagonistultrafiltration levosimendannesiritiderolofylline serelaxintolvaptantonapofylline vs placebo or controlvs active treatment      

Filter

Group by Group by... nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition MA  in first nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in second nothing pathology treatment patient comparator classe classe comparator mechanism clinical condition  in third	Description Synopsis Comparison Treatments Patients Characteristics Method Risk of bias References None Tools Indexation					Results Global trial result Main results All results All result tag NCT results	All cause death (11)hospitalisation for heart failure (3)Death from any cause or hospitalization for heart failure (2)amelioration of Dyspnea at 24 h (2)30-day death (2) Options Numeric bar chart forest plot medians
Trial	Studied trt	Control trt	patients	tags	ROB	Trial result	All cause death	hospitalisation for heart failure
atrial natriuretic peptide
nesiritide
NSGET (comparative trial), 2000	nesiritide	control			Low risk of bias	remark
VMAC (intravenous neseritide), 2002      NCT	nesiritide	placebo			Low risk of bias	remark
NSGET (efficacy trial), 2000	nesiritide	placebo			Low risk of bias	negative
PRECEDENT, 2002      NCT	nesiritide	dobutamine			Exploratory	remark
VMAC (24h), 2002      NCT	nesiritide	nitroglycerin			Risk of bias	negative
calcium sensitiser
levosimendan
RUSSLAN, 2002	levosimendan	placebo			Low risk of bias	remark
REVIVE-I, 2003	levosimendan	placebo			Exploratory	remark
REVIVE II, 2013      NCT	levosimendan	placebo			Low risk of bias	-
LIDO, 2002	levosimendan	dobutamine			Low risk of bias	remark
SURVIVE, 2007    NCT	levosimendan	dobutamine			Low risk of bias	negative
CASINO	levosimendan	dobutamine			Low risk of bias	remark
diuretics
rolofylline
PROTECT, 2010    NCT	rolofylline	placebo			Low risk of bias	negative
endothelin receptor antagonist
not classified
RITZ 4 importé, 2003	tezosentan	placebo			Low risk of bias	remark
VERITAS II, 2007      NCT	tezosentan	placebo			Low risk of bias	remark
RITZ-5, 2003	tezosentan	placebo			Low risk of bias	remark
VERITAS I, 2006      NCT	tezosentan	placebo			Low risk of bias	remark
nesiritide
NSGET (comparative trial), 2000	nesiritide	control			Low risk of bias	remark
FUSION 2, 2008        NCT	nesiritide	placebo			Low risk of bias	remark
BNP-CARDS, 2007          NCT	nesiritide	placebo			Low risk of bias	remark
PROACTION, 2003	nesiritide	placebo			Low risk of bias	negative
NSGET (efficacy trial), 2000	nesiritide	placebo			Low risk of bias	negative
VMAC (intravenous neseritide), 2002      NCT	nesiritide	placebo			Low risk of bias	remark
ASCEND-HF, 2011        NCT	nesiritide	placebo			Low risk of bias	negative
PRECEDENT, 2002      NCT	nesiritide	dobutamine			Exploratory	remark
VMAC (24h), 2002      NCT	nesiritide	nitroglycerin			Risk of bias	negative
FUSION 1, 2004    NCT	nesiritide	standard care			Low risk of bias	remark
new drug under development
not classified
UNLOAD						-
AVOID HF    NCT	ultrafiltration					-
CARRESS-HF	ultrafiltration					-
B-CONVINCED, 2009    NCT	beta-blockade continuation	discontinuation				-
levosimendan
RUSSLAN, 2002	levosimendan	placebo			Low risk of bias	remark
REVIVE-I, 2003	levosimendan	placebo			Exploratory	remark
REVIVE II, 2013      NCT	levosimendan	placebo			Low risk of bias	-
LIDO, 2002	levosimendan	dobutamine			Low risk of bias	remark
CASINO	levosimendan	dobutamine			Low risk of bias	remark
SURVIVE, 2007    NCT	levosimendan	dobutamine			Low risk of bias	negative
nesiritide
NSGET (comparative trial), 2000	nesiritide	control			Low risk of bias	remark
NSGET (efficacy trial), 2000	nesiritide	placebo			Low risk of bias	negative
PROACTION, 2003	nesiritide	placebo			Low risk of bias	negative
BNP-CARDS, 2007          NCT	nesiritide	placebo			Low risk of bias	remark
VMAC (intravenous neseritide), 2002      NCT	nesiritide	placebo			Low risk of bias	remark
ASCEND-HF, 2011        NCT	nesiritide	placebo			Low risk of bias	negative
FUSION 2, 2008        NCT	nesiritide	placebo			Low risk of bias	remark
PRECEDENT, 2002      NCT	nesiritide	dobutamine			Exploratory	remark
VMAC (24h), 2002      NCT	nesiritide	nitroglycerin			Risk of bias	negative
FUSION 1, 2004    NCT	nesiritide	standard care			Low risk of bias	remark
rolofylline
PROTECT, 2010    NCT	rolofylline	placebo			Low risk of bias	negative
serelaxin
RELAX-AHF, 2013      NCT	serelaxin	placebo				-
Pre-RELAX-AHF, 2009      NCT	serelaxin	placebo			Low risk of bias	-
relaxin
serelaxin
Pre-RELAX-AHF, 2009      NCT	serelaxin	placebo			Low risk of bias	-
RELAX-AHF, 2013      NCT	serelaxin	placebo				-
ultrafiltration
not classified
UNLOAD						-
CARRESS-HF	ultrafiltration					-
AVOID HF    NCT	ultrafiltration					-
vasopressin antagonist
tolvaptan
EVEREST Outcome, 2007	tolvaptan	placebo				-
EVEREST Clinical Status , 2007      NCT	tolvaptan	placebo				-
Udelson, 2007      NCT	tovalpan	placebo			Low risk of bias	suggesting